Genetically Modified Human Embryonic Stem Cells Relieve Symptomatic Motor Behavior in a Rat Model of Parkinson′s Disease

  • 길광수 (마리아 기초의학연구소/마리아 생명공학연구소) ;
  • 이영재 (마리아 기초의학연구소/마리아 생명공학연구소) ;
  • 김은영 (마리아 기초의학연구소/마리아 생명공학연구소) ;
  • 이창현 (마리아 기초의학연구소/마리아 생명공학연구소) ;
  • 이훈택 (건국대학교) ;
  • 정길생 (건국대학교) ;
  • 박세필 (마리아 기초의학연구소/마리아 생명공학연구소) ;
  • 임진호 (마리아 병원)
  • Published : 2003.06.01

Abstract

Embryonic stem cells have several characteristics suitable for cell replacement therapy. To investigate a possibility of using human embryonic stem cell (hESC) as a carrier of therapeutic gene(s), hESC (MB03) was co-transfected with cDNAS coding for tyrosine hydroxylase (TH) and GTP cyclohydrolase Ⅰ (GTPCH Ⅰ) and bulk-selected using neomycin and hygromycin-B. Successful transfection was confirmed by western immunoblotting and RT-PCR. The genetically modified hESC (bk-THGC) relieved apomorphine-induced asymmetric motor behavior by approximately 54% when grafted into striatum of 6-OHDA-denervated rat brain. The number of rotation, however, increased up to 176+18% in 6 weeks when sham-grafted compared with number of rotation before graft. Immunohistochemical staining revealed that the grafted hESC survived and expressed TH for at least 6 weeks while the experiment was continued.

Keywords